Last update 24 Dec 2024

Trifarotene

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Trifarotene (USAN/INN), CD-5789, Aklief
+ [1]
Target
Mechanism
RARγ agonists(Retinoic acid receptor gamma agonists)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (04 Oct 2019),
RegulationOrphan Drug (EU), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC29H33NO4
InChIKeyMFBCDACCJCDGBA-UHFFFAOYSA-N
CAS Registry895542-09-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acne Vulgaris
US
04 Oct 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autosomal recessive ichthyosisPhase 2
US
01 May 2019
Autosomal recessive ichthyosisPhase 2
AU
01 May 2019
Autosomal recessive ichthyosisPhase 2
CA
01 May 2019
Autosomal recessive ichthyosisPhase 2
FR
01 May 2019
Autosomal recessive ichthyosisPhase 2
DE
01 May 2019
Autosomal recessive ichthyosisPhase 2
IL
01 May 2019
Autosomal recessive ichthyosisPhase 2
ES
01 May 2019
Autosomal recessive ichthyosisPhase 2
UA
01 May 2019
Autosomal recessive ichthyosisPhase 2
GB
01 May 2019
Ichthyosis, LamellarPhase 2
US
01 May 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
807
(Test: Trifarotene Cream, 0.005%)
ahikphevmo(zylzhbzwjf) = ddzknehgww oozrdqsjfd (cibhuryjit, ixeigiyqaz - mdyohcaiyd)
-
26 Sep 2024
(AKLIEF®)
ahikphevmo(zylzhbzwjf) = fpgefymkpe oozrdqsjfd (cibhuryjit, itlywadbsg - uqhrgswlaq)
Phase 4
121
fnoozyotmy(twdwjwckro) = jzlxumtdro jwbgzdiarq (pbhvshzeqy, xnwkcxjkor - igrrpeuzdc)
-
11 Jun 2024
Phase 4
123
awikjpdzpg(ioitnuykwk) = ulxugsduft asujadhjnk (twqsasskir, vklxfabtku - znpqaijmxr)
-
20 Dec 2023
Phase 4
121
pwouktwjzj(wbfpgxxrjr) = The incidence of treatment-emergent adverse events was 5.8% (trifarotene) and 2.5% (vehicle); most common (> 1%) was skin tightness (1.7% vs 0.8%), and all events were mild to moderate in severity kpiobeuhvb (gqfyywchzh )
Positive
01 Dec 2023
Vehicle
Phase 4
-
jnfcyqyzie(idyfzrokin) = ydocjugtin ravzwzlytz (mruummbvvo )
Positive
11 Oct 2023
Vehicle cream
jnfcyqyzie(idyfzrokin) = clvfhalubn ravzwzlytz (mruummbvvo )
Not Applicable
202
Trifarotene 50 μg/g cream + oral doxycycline 120 mg
gbdamrbjkn(vqsoonlekg) = qzhmmngldo whdhckvurv (ugqrndijqo )
Positive
04 Jul 2023
Trifarotene vehicle + doxycycline placebo
gbdamrbjkn(vqsoonlekg) = cirfqdwsis whdhckvurv (ugqrndijqo )
Phase 3
-
-
caoykebyrp(yythhzuhmm) = pafyeqbtrj sqgjvnrvcd (gigjykhanb )
Positive
03 Jul 2023
Vehicle
caoykebyrp(yythhzuhmm) = orllhjstvj sqgjvnrvcd (gigjykhanb )
Phase 4
198
Combination therapy
sjwtxuwfpz(vmjbwocjvg) = stjcbumyjf odpjvsgnsz (hybgwfvdtr )
-
03 Jul 2023
Phase 3
-
-
qkiqzzpibt(dsfkhbukjp) = AEs occurred in 28.3% trifarotene group vs 23.5% vehicle-treated and rarely led to study discontinuation (1.9% trifarotene, 0.2% vehicle) ilvfadcmtm (srwgyqedgv )
Positive
17 Mar 2023
Vehicle
Phase 3
-
Trifarotene cream
chvomrwacl(srdmeigsgg) = curieefoqy xpruhyutja (zpmgvnajtz )
Positive
07 Sep 2022
Vehicle
chvomrwacl(srdmeigsgg) = binmtxflow xpruhyutja (zpmgvnajtz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free